Clinical Trial Update: Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing a Phase 1/2 study of nanoliposomal irinotecan (nal-IRI, Onivyde) in combination with carboplatin for advanced or metastatic gas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: GEP-NET | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION